Journal of Thoracic Oncology

《胸肿瘤杂志》(JTO)是国际肺癌研究协会的官方期刊，是关于所有胸肿瘤的预防、检测、诊断和治疗相关主题的主要教育和信息出版物。JTO强调多学科方法，包括原始的研究综述和观点。听众包括流行病学家、医学肿瘤学家、放射肿瘤学家、胸外科医生、肺科医生、放射科医生、病理学家、核医学医生和对胸外科有特殊兴趣的研究科学家。该杂志有兴趣接受手稿处理流行病学，预防，筛选，早期发现，分期，治愈和治疗胸部恶性肿瘤。有关烟草控制和戒烟的意见值得关注，特别是在与肺癌流行病学和治疗结果直接相关的领域。该杂志也欢迎提交病理和组织学分类和新的成像和支气管镜方法。关于新的系统疗法的提交，特别是在生物标志物靶标、基因组学、免疫学和细胞疗法领域是有兴趣的。新颖的放射治疗和外科技术很有价值。鼓励提交随机II期和III期试验，以及对个体参与者数据的meta分析。基础科学研究必须具有直接的临床和翻译相关性。

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.